BRIEF-Regenxbio Enters Settlement And Release Agreement With Glaxosmithkline On March 18, 2026 - SEC Filing

REGENXBIO, Inc. +3.26%
GlaxoSmithKline plc Sponsored ADR +2.14%

REGENXBIO, Inc.

RGNX

9.49

+3.26%

GlaxoSmithKline plc Sponsored ADR

GSK

58.35

+2.14%

March 20 (Reuters) - SEC Filing:

  • REGENXBIO INC - ENTERS SETTLEMENT AND RELEASE AGREEMENT WITH GLAXOSMITHKLINE ON MARCH 18, 2026 - SEC FILING

  • REGENXBIO INC - TO PAY $10.0 MILLION TO GLAXOSMITHKLINE FOR ALLEGED UNDERPAYMENT OF SUBLICENSE FEES - SEC FILING

  • REGENXBIO INC - SETTLEMENT AGREEMENT INCLUDES MUTUAL RELEASES OF PAST AND CERTAIN FUTURE CLAIMS - SEC FILING

  • REGENXBIO INC - TO CONTINUE TO PAY GSK AMOUNTS RECEIVED FROM SUBLICENSEES PURSUANT TO EXISTING SUBLICENSE AGREEMENTS - SEC FILING

Source text: [ID:n0001193125-26-117913]

Further company coverage: RGNX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.